School of Medicine

Two researchers at Washington University in St. Louis took a closer look at the signals that coordinate a heartbeat at the molecular level. What they found may provide new insights into different heart conditions and how to develop better therapies.

New research from the School of Medicine suggests that transposable elements in various cancers potentially may be used to harness novel immunotherapies against tumors that don’t typically respond to immune-based treatments.

Three School of Medicine researchers — Enmanuel Perez, Ibrahim Saliu and Steffen Storck — have received funding from the Alzheimer’s Association for projects that aim to study and make progress against the disease.

School of Medicine scientists are working to minimize the risk of another devastating coronavirus pandemic by designing a vaccine that reduces sickness and death caused by all potentially deadly coronaviruses, including ones that have not yet affected people. The research is supported by an $8 million grant from the National Institutes of Health (NIH).

Daniel C. Link, MD, a highly regarded physician-scientist who treats patients with leukemia and also conducts innovative research, has been named director of the Division of Oncology in the Department of Medicine at the School of Medicine.

The School of Medicine’s Cynthia Rogers, MD, and co-investigator Christopher Smyser, MD, have received a MERIT award from the National Institutes of Health (NIH) to support their research focused on preterm babies’ brains as the children age.

Four Washington University in St. Louis faculty members have been named Fellows of the American Institute for Medical and Biological Engineering: Hongyu An, Elliot Elson, Srikanth Singamaneni and Jessica Wagenseil.

Makedonka Mitreva, a professor of medicine and of genetics at the School of Medicine, has been elected to the American Academy of Microbiology in recognition of her contributions to the field of microbiology.

People infected with COVID-19 who then took the antiviral medication Paxlovid within five days after testing positive experienced a reduced risk of long-term health problems, hospitalization and death for up to six months, according to a study by researchers at the School of Medicine and the Veterans Affairs St. Louis Health Care system.

New research led by Washington University researchers identifies a common genetic signature that may increase a person’s risk of developing substance use disorders. The work eventually could lead to universal therapies to treat multiple substance use disorders and potentially help people diagnosed with more than one.